- Home
- FLC vs ANTX Comparison
FLC vs ANTX Comparison
Compare FLC & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.4M | 172.9M |
| IPO Year | 2003 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FLC | ANTX |
|---|---|---|
| Price | $15.40 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 42.6K | ★ 295.2K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.33 | $1.00 |
| 52 Week High | $18.09 | $7.19 |
Technical Indicators
Market Signals| Indicator | FLC | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.20 | 29.98 |
| Support Level | $15.33 | $2.87 |
| Resistance Level | $15.85 | $5.15 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 13.46 | 14.64 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.